Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome

Summary

A deficiency of von Willebrand factor (vWF)-cleaving protease, either due to a congenital deficiency or to the presence of a protease inhibitor of vWF-cleaving protease has been associated with thrombotic thrombocytopenic purpura (TTP). We have studied vWF-cleaving protease in diarrhoea-associated haemolytic uraemic syndrome (D+ HUS), which shares clinical features with TTP. 29 children with acute D+ HUS and 13 control children were studied.

vWF-cleaving protease activity was normal (range 50-150%) in 39 of 42 plasma samples. Levels of protease activity between 25 and 50% were noted in plasma from two D+ HUS patients. One D+HUS patient, who had clinical features of TTP, had a vWF-cleaving protease inhibitor producing a severe deficiency of vWF-cleaving protease.

Thus a deficiency of vWF-cleaving protease appears to be atypical in D+HUS. The detection of a vWF-cleaving protease inhibitor in one patient suggests it may be associated with infection such as E. coli 0157.

Key words

Von Willebrand factor-cleaving protease - haemolytic uraemic syndrome

• References

• 1 Frishberg Y, Obrig TG, Kaplan BS. Hemolytic Uremic Syndrome. In: Holliday MA, Barratt TM, Avner ED. (eds). Pediatric Nephrology, 3rd edn. Baltimore, Maryland: Williams and Wilkins; 1994: 871-89.
• 2 Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: clinical and epidemiological aspects. Arch Dis Child 1990; 65: 716-21.
• 3 Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli 0157:H7 and the hemolytic uremic syndrome. N Engl J Med 1995; 333: 364-8.
• 4 Lingwood CA, Law H, Richardson S, Petric M. et al. Glycolipid binding of purified and recombinant Escherichia coli produced by verotoxin in vitro. J Biol Chem 1987; 262: 8834-9.
• 5 Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80: 1890-5.
• 6 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
• 7 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the haemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
• 8 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-46.
• 9 Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
• 10 Nevard CHF, Jurd KM, Lane DA, Phillipou H, Haycock GB, Hunt BJ. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 1997; 78: 1450-5.
• 11 Nevard CHF, Blann AD, Jurd KM, Haycock GB, Hunt BJ. Endothelial cell activation and injury in childhood haemolytic uraemic syndrome. Paediatr Nephrol 1999; 13: 487-92.
• 12 Mannucci PM. Von Willebrand Factor (vWF)-cleaving protease: changes in health and disease. Workshop on vWF and TTP Bethesda, Maryland: 2000 (abstract).
• 13 Habib R. Pathology of the Hemolytic Uremic Syndrome. In: Kaplan BS, Trompeter RS, Moake JL. (eds). Hemolytic Uremic Syndrome and Thrombocytopenic Purpura. New York: Marcel Dekker; 1992: 315-53.
• 14 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N. Y Pathol Soc 1924; 21-4.
• 15 Moake JL. Moschcowitz, multimers and metalloprotease. N Engl J Med 1998; 339: 1629-31.